PRIMARY STUDY
Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin
Key Findings: Resulting data suggests that the liquid oral use of CBDV (600mg) can modulate atypical striatal circuitry towards neurotypical function in this patient population.
Type of Study: Double Blind Clinical Trial
Study Result: Positive
Study Location(s): Germany, Netherlands, Spain, United Kingdom
Year of Pub: 2021
Cannabinoids Studied: Cannabinoid (unspecified), Cannabidivarin (CBDV)
Phytocannabinoid Source: Unspecified
Dosage: 600 mg